English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The COVID-19 pandemic is a global crisis creating severe disruptions across the economy and health system. Insights into how to better understand and treat COVID-19 are desperately needed. Early studies have focused on the clinical characteristics [1–3], epidemiology [1, 4, 5], and genomic characterization [6–8] of SARS-CoV-2 infection. These studies have also highlighted the value and importance of transparent data sharing across countries, which have enabled the live tracking of the disease widespread worldwide [9, 10]. The role of host genetics in impacting susceptibility and severity of COVID-19 has been less studied. Previous work has supported the role of human leukocyte antigen (HLA) in susceptibility [11] and severity [12] for several viral infections. Moreover, a synonymous variant in the IFN-induced transmembrane protein-3 gene has been reported to cause severe clinical outcomes in patients infected with H7N9 and H1N1 influenza viruses [13, 14], although results did not reach established P value thresholds (P < 5 × 10). In addition, candidate variant studies have suggested host factors that are critical for severe disease in other coronavirus infections, such as infections due to the related SARS-CoV [15]. Given the importance and urgency of exploring the role of the host genome in conjunction with COVID-19 clinical and genomic variability, and the recognition that this can only be achieved with the combined effort of the scientific community, we launched the ‘COVID-19 Host Genetics Initiative’. This initiative brings together the human genetics community to generate, share, and analyze data to learn the genetic determinants of COVID-19 susceptibility, severity, and outcomes. Such discoveries could help to identify individuals at unusually high or low risk, generate hypotheses for drug repurposing, and contribute to global knowledge of the biology of SARS-CoV-2 infection and disease. The initiative has three main goals:

european journal of human genetics

The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic